Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Approved Drug for Skin Condition Shown Safe at Higher Dose

Source: Dr. Jonathan Aschoff


September 5, 2023 ( Newswire) Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.

Biofrontera Inc. (BFRI:NASDAQ) announced that three tubes of its Ameluz topical gel, in combination with photodynamic therapy, exhibited a positive safety profile when used to treat facial and scalp actinic keratosis, reported ROTH Capital Partners analyst Dr. Jonathan Aschoff in an August 28 research note.

The currently approved dose in the States is one tube.

278% Return Implied

ROTH reiterated its price target on the Massachusetts-based biopharma of US$33 per share. Biofrontera's current share price, in comparison, is about US$8.72. Given these figures, the projected potential return for investors is material, at 278%.

Biofrontera is a Buy.

New Safety Data

Aschoff summarized the findings of the recent Phase 1 clinical trial, in which treatment using three tubes of Ameluz and photodynamic therapy administered via the company's RhodoLED XL lamp was evaluated for safety and tolerability.

None of the patients reported any serious adverse events or quit the study because of a treatment-associated adverse event.

The adverse events that did occur were expected due to "the therapeutic principle of photodynamic therapy," wrote Aschoff, and were consistent with those linked to the use of one tube of Ameluz in the same indication. Typically, effects that occurred resolved in one to four days after photodynamic therapy but sometimes lasted one to two weeks.

Overall, patients tolerated treatment well.

Pursuit of Label Expansion

Biofrontera intends to submit these safety data to the U.S. Food and Drug Administration, in Q4/23, to support expansion of its Ameluz label to include use of up to three tubes per treatment, Aschoff reported.

An expansion, the analyst added, would make "Ameluz more competitive, given the ability to treat more surface area per treatment." Therefore, treatment could be administered in fewer office visits, another positive.

Superior Efficacy

Already, Ameluz differentiates itself from competitors, Aschoff pointed out, because it is the only treatment of this type in which the drug is administered broadly over a field versus being applied to individual keratoses.

"The treatment is particularly effective because the procedure treats both visible actinic keratosis lesions as well as invisible lesions that lie within the field defined by the visible lesions," explained Aschoff. "This application difference is part of why Ameluz's efficacy is unmatched by competitors."

More Data Early Next Year

In other news, Biofrontera has advanced the Phase 3 trial assessing Ameluz plus photodynamic therapy in basal cell carcinoma to the point where the last of the 187 enrolled patients will complete final assessment in Q1/24, Aschoff noted.

Data readout should happen soon afterward.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That's all it takes to get an article published on Investor Ideas - Learn More - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on